falciparum malaria


Also found in: Dictionary, Thesaurus, Medical.

falciparum malaria

[fal′sip·ə·rəm mə′ler·ē·ə]
(medicine)
A severe form of malaria caused by Plasmodium falciparum and characterized by sudden attacks of chills, fever, and sweating at irregular intervals; the infecting organism usually localizes in a specific organ, causing capillary blockage. Also known as alged malaria; estivoautumnal malaria; malignant malaria; pernicious malaria.
References in periodicals archive ?
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): An open-label, randomised trial.
Leucopenia (below 4000/ [micro]L) was observed in only 8 (11.4%) cases and leucocytosis (above 11,000/[micro]L) was seen in 4 patients (5.7%) out of the total 70 cases, all 4 were suffering from falciparum malaria. This study did not show significant statistical difference in total leucocyte count between these two species (p-value > 0.05) [Table 3].
Predicting the clinical outcome of severe falciparum malaria in african children: Findings from a large randomized trial.
Clinical profile of Falciparum malaria in a tertiary care hospital.
Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment.
Development and testing of LAMP assay for diagnosis of Plasmodium falciparum malaria. Ethinicity and Disease., 2009; 19:23-24.
At the time of those studies, mefloquine was the treatment of choice for uncomplicated multiresistant falciparum malaria. A standard dose of 15 mg/kg of mefloquine became ineffective in treating acute falciparum malaria in an area with deteriorating multidrug resistance on the Thai-Myanmar border.
This study investigated the effect of age on the concentration of mefloquine in the plasma and erythrocytes of patients with uncomplicated falciparum malaria in the Amazon basin.
A study conducted by Qurban et al, reported 93.33% of thrombocytopenia in patients having Plasmodium vivax.15 In contrast to our study Jadhav and Patkar conducted an extensive study regarding pattern of thrombocytopenia in patients having vivax and falciparum malaria. They documented thrombocytopenia in both groups of patients but severe thrombocytopenia, (platelets 20,000 or less) was more consistent with Plasmodium falciparum malaria, while Memon has reported thrombocytopenia in malaria to be about 70%.16,17
Comparative efficacies of Artemisinin combination therapies in Plasmodium falciparum malaria and polymorphism of PfATPase6, pfcrt, pfdhfr and pfdhps genes in tea gardens of Jalpaiguri district.
Over a 2-year period, 1,241 patients aged 6 months to 65 years with acute, uncomplicated falciparum malaria were randomly assigned to receive either 2 mg or 4 mg of oral artesunate for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy.